Banning Xylazine Didn't Shrink the Tranquilizer Supply. It Just Renamed the Problem Medetomidine.

Researchers David Zhu of Virginia Commonwealth University and Sehun Oh of Ohio State University set out to answer a specific policy question: when a state formally schedules a drug-supply adulterant as a controlled substance — making it illegal to possess, not just illegal to use in combination with something else — does the illicit market actually contain less of it? Their analysis, published in the International Journal of Drug Policy, used nearly 114,000 drug-checking reports collected between 1999 and 2025 — 101,987 for xylazine, 12,085 for medetomidine — comparing nine states that scheduled xylazine against five states that only criminalized combining it with other drugs, without scheduling the substance itself.

Scheduling xylazine didn’t make the tranquilizer problem smaller. It made the tranquilizer problem worse in a way that doesn’t show up on the graph labeled “xylazine.”

States that scheduled xylazine saw roughly 1,500 additional medetomidine detections per 100,000 drug samples compared to states that only criminalized it — a substitution effect large enough to be the study’s headline finding, not statistical noise. Medetomidine is medetomidine’s own kind of bad news: a veterinary alpha-2 sedative, chemically similar to xylazine but more potent, that is not reversed by naloxone and can produce withdrawal severe enough to require ICU-level care. Zhu and Oh’s authors describe the pattern with a term drug-policy researchers have used for decades — the “iron law of prohibition” — the observation that cracking down on one substance in a drug supply chain doesn’t shrink demand, it pushes suppliers toward whatever chemically similar substance regulation hasn’t caught up to yet.

The theory, confirmed by what’s already happening in North Carolina

This isn’t a hypothetical risk the study is warning about — it’s a pattern already visible on the ground. The UNC Street Drug Analysis Lab, which has tested more than 23,000 drug samples and logged over 536 unique substances, reports medetomidine has already overtaken xylazine as the dominant tranquilizer adulterant in parts of North Carolina’s illicit supply — one of the clearest real-world confirmations of the substitution effect the peer-reviewed data describes. Harm-reduction organizations serving that population now face a second-order cost the original scheduling debate never accounted for: medetomidine test strips run roughly five to six times the cost of fentanyl test strips, meaning the same funding buys detection for a fraction of the population it used to cover, even before accounting for this year’s federal restrictions on using grant dollars for test strips at all.

This is not a one-off pattern — it’s the shape of the whole synthetic-drug supply now

Zoom out from xylazine specifically, and the substitution pattern isn’t an anomaly — it’s the dominant shape of the current illicit drug market. The DEA has identified 22 unique nitazene compounds since 2020, synthetic opioids that can match or exceed fentanyl’s potency; 21 are now Schedule I, and in June 2025 DEA moved to schedule seven more benzimidazole-opioid variants. Nitazenes are increasingly showing up mixed into counterfeit pills and fentanyl powder without users’ knowledge, sometimes requiring multiple doses of naloxone to reverse an overdose that a single dose would have handled a few years ago.

The global data tells the same story at larger scale. UNODC’s World Drug Report 2026 documented 755 novel psychoactive substances circulating in global drug markets in 2024, with 118 reported for the first time that year alone — roughly five times more distinct drug types turning up in seizures than were common before 2000. The report flags an entirely new emerging opioid family researchers are calling “orphines,” already linked to 18 confirmed deaths across five EU member states between June 2024 and January 2026, detected in 11 countries. Each new compound restarts the same cycle: it isn’t illegal yet, drug-checking programs don’t have a strip for it yet, and clinicians don’t have a protocol for its specific withdrawal profile yet.

None of this is an argument against scheduling dangerous substances — xylazine causes real, severe harm on its own terms, independent of what replaces it. It’s an argument that scheduling alone, treated as a complete policy response, has a predictable and now peer-reviewed-documented failure mode: it doesn’t make the supply safer, it makes the supply less legible to the people trying to test it, treat it, and survive it. A drug-checking infrastructure that can adapt as fast as the substances mutating past it — not one more scheduling action after the fact — is what the data in this study is actually arguing for.

None of this is an argument against scheduling dangerous substances — xylazine causes real, severe harm on its own terms, independent of what replaces it.